+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination



Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination



Plos One 10(9): E0139062-E0139062



Costs associated with HPV-related diseases such as cervical dysplasia, cervical cancer, and genital warts have not been evaluated in Sweden. These costs must be estimated in order to determine the potential savings if these diseases were eradicated and to assess the combined cost-effectiveness of HPV vaccination and cervical cancer screening. The present study aimed to estimate prevention, management, and treatment costs associated with cervical dysplasia, cervical cancer, and genital warts from a societal perspective in Sweden in 2009, 1 year before the quadrivalent HPV vaccination program was implemented. Data from the Swedish cervical cancer screening program was used to calculate the costs associated with prevention (cytological cervical cancer screening), management (colposcopy and biopsy following inadequate/abnormal cytological results), and treatment of CIN. Swedish official statistics were used to estimate treatment costs associated with cervical cancer. Published epidemiological data were used to estimate the number of incident, recurrent, and persistent cases of genital warts; a clinical expert panel assessed management and treatment procedures. Estimated visits, procedures, and use of medications were used to calculate the annual cost associated with genital warts. From a societal perspective, total estimated costs associated with cervical cancer and genital warts in 2009 were €106.6 million, of which €81.4 million (76%) were direct medical costs. Costs associated with prevention, management, and treatment of CIN were €74 million; screening and management costs for women with normal and inadequate cytology alone accounted for 76% of this sum. The treatment costs associated with incident and prevalent cervical cancer and palliative care were €23 million. Estimated costs for incident, recurrent and persistent cases of genital warts were €9.8 million. Prevention, management, and treatment costs associated with cervical dysplasia, cervical cancer, and genital warts are substantial. Defining these costs is important for future cost-effectiveness analyses of the quadrivalent HPV vaccination program in Sweden.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057527012

Download citation: RISBibTeXText

PMID: 26398189


Related references

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia. Asian Pacific Journal of Cancer Prevention 18(7): 2011-2017, 2017

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26(35): 4513-4518, 2008

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. International Journal of Technology Assessment in Health Care 26(2): 183-191, 2010

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care 24(1): 10-19, 2008

Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. International Journal of Epidemiology 47(2): 634-641, 2018

Preventing cervical cancer and other human papillomavirus-related diseases: recent advances in prophylactic vaccination. Vaccine 24(Suppl. 1): S1-S31, 2006

Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. Journal of the American Academy of Dermatology 68(1): 179-180, 2013

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26(1): 128-139, 2007

Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveillance 14(6): -, 2009

Introduction: The Complexity and Challenge of Preventing, Treating, and Managing Blood Diseases in the Developing Countries. Hematology/Oncology Clinics of North America 30(2): 233-246, 2016

Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet. Infectious Diseases 17(1): 68-77, 2016

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value in Health 11(7): 1022-1032, 2008

Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine 32(51): 6941-6947, 2015

Anaphylaxis following quadrivalent human papillomavirus vaccination. Cmaj 179(6): 525-533, 2008

Anaphylaxis following quadrivalent human papillomavirus vaccination. Yearbook of Obstetrics Gynecology and Women's Health 2009: 156-157, 2009